Bio-Techne（TECH）株式概要
バイオテクネ・コーポレーションは、その子会社とともに、研究、診断、バイオプロセス市場向けのライフサイエンス試薬、機器、サービスを世界中で開発、製造、販売している。 詳細
TECH Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bio-Techne Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$48.21 |
| 52週高値 | US$72.16 |
| 52週安値 | US$43.20 |
| ベータ | 1.4 |
| 1ヶ月の変化 | -11.03% |
| 3ヶ月変化 | -11.96% |
| 1年変化 | 3.06% |
| 3年間の変化 | -42.26% |
| 5年間の変化 | -53.40% |
| IPOからの変化 | 7,425.46% |
最新ニュース
Recent updates
ナラティブの更新 • May 12
TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future Upside
Analysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).
ナラティブの更新 • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.ナラティブの更新 • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).ナラティブの更新 • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).ナラティブの更新 • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).
ナラティブの更新 • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.分析記事 • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...ナラティブの更新 • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).ナラティブの更新 • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking Alphaナラティブの更新 • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).ナラティブの更新 • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).ナラティブの更新 • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.ナラティブの更新 • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).分析記事 • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...ナラティブの更新 • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.ナラティブの更新 • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.ナラティブの更新 • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.分析記事 • Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation's ( NASDAQ:TECH ) price-to-earnings (or "P/E") ratio of 70x might make it look like a strong...分析記事 • May 29
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
Bio-Techne Corporation ( NASDAQ:TECH ), might not be a large cap stock, but it saw significant share price movement...Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alpha
新しいナラティブ • Aug 22
Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges
Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.株主還元
| TECH | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 11.3% | 4.1% | 1.1% |
| 1Y | 3.1% | 8.3% | 28.7% |
業界別リターン: TECH過去 1 年間で8.3 % の収益を上げたUS Life Sciences業界を下回りました。
リターン対市場: TECHは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。
価格変動
| TECH volatility | |
|---|---|
| TECH Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: TECH 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: TECHの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1976 | 3,100 | Kim Kelderman | www.bio-techne.com |
バイオテクネ・コーポレーションは子会社とともに、研究、診断、バイオプロセス市場向けのライフサイエンス試薬、機器、サービスを開発、製造、販売している。同社は「タンパク質科学」、「診断と空間生物学」の2つのセグメントで事業を展開している。タンパク質科学部門では、サイトカインや成長因子、抗体、低分子化合物、組織培養血清、細胞選択技術など、ライフサイエンス研究、診断、細胞・遺伝子治療の様々な局面で使用される生物学的試薬を開発・製造している。この部門はまた、自動ウェスタンブロットや多重ELISAワークフロー用のプロテオミクス分析ツールも提供しており、手動および自動のタンパク質分析機器と、様々な生物学的流体中のタンパク質の定量に使用するイムノアッセイで構成されている。診断薬およびゲノミクス事業では、規制診断薬市場向けのコントロール、キャリブレーター、診断アッセイ、エクソソームベースの分子診断アッセイ、空間ゲノムおよび組織生検分析用の高度な組織ベースのin-situハイブリダイゼーションアッセイ、研究および臨床用途の遺伝学および腫瘍学キットを含む診断薬の開発および製造、遺伝的キャリアスクリーニング、腫瘍学診断、分子コントロール、研究用の製品、および様々な診断用途で使用される血液学、血液化学およびガス、凝固コントロールおよび試薬用の機器およびプロセスコントロール製品の販売を行っている。旧社名はテクネ・コーポレーションで、2014年11月にバイオテクネ・コーポレーションに社名変更した。バイオテクネ・コーポレーションは1976年に法人化され、ミネソタ州ミネアポリスに本社を置いている。
Bio-Techne Corporation 基礎のまとめ
| TECH 基礎統計学 | |
|---|---|
| 時価総額 | US$7.55b |
| 収益（TTM） | US$109.50m |
| 売上高(TTM) | US$1.21b |
68.9x
PER（株価収益率6.2x
P/SレシオTECH は割高か？
公正価値と評価分析を参照収益と収入
| TECH 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.21b |
| 売上原価 | US$406.84m |
| 売上総利益 | US$803.97m |
| その他の費用 | US$694.47m |
| 収益 | US$109.50m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.70 |
| グロス・マージン | 66.40% |
| 純利益率 | 9.04% |
| 有利子負債／自己資本比率 | 9.6% |
TECH の長期的なパフォーマンスは？
過去の実績と比較を見る| Bio-Techne 配当日 | |
|---|---|
| 配当落ち日 | May 18 2026 |
| 配当支払日 | May 29 2026 |
| 配当落ちまでの日数 | 7 days |
| 配当支払日までの日数 | 4 days |
TECH 配当は確実ですか？
TECH 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/24 13:21 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bio-Techne Corporation 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |